These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30688316)

  • 41. Ankle contractures and functional motor decline in Duchenne muscular dystrophy.
    Woof AL; Selby K; Harris SR
    Brain Dev; 2022 Feb; 44(2):105-113. PubMed ID: 34629214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can simple and low-cost motor function assessments help in the diagnostic suspicion of Duchenne muscular dystrophy?
    Pereira AC; Araújo APQC; Ribeiro MG
    J Pediatr (Rio J); 2020; 96(4):503-510. PubMed ID: 31009620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between muscle strength and motor function in Duchenne muscular dystrophy.
    Nunes MF; Hukuda ME; Favero FM; Oliveira AB; Voos MC; Caromano FA
    Arq Neuropsiquiatr; 2016 Jul; 74(7):530-5. PubMed ID: 27487372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration.
    Goemans N; Wong B; Van den Hauwe M; Signorovitch J; Sajeev G; Cox D; Landry J; Jenkins M; Dieye I; Yao Z; Hossain I; Ward SJ;
    PLoS One; 2020; 15(6):e0232870. PubMed ID: 32555695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of a wearable device to assess sleep and motor function in Duchenne muscular dystrophy.
    Siegel BI; Cakmak A; Reinertsen E; Benoit M; Figueroa J; Clifford GD; Phan HC
    Muscle Nerve; 2020 Feb; 61(2):198-204. PubMed ID: 31725915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.
    Connolly AM; Florence JM; Cradock MM; Malkus EC; Schierbecker JR; Siener CA; Wulf CO; Anand P; Golumbek PT; Zaidman CM; Philip Miller J; Lowes LP; Alfano LN; Viollet-Callendret L; Flanigan KM; Mendell JR; McDonald CM; Goude E; Johnson L; Nicorici A; Karachunski PI; Day JW; Dalton JC; Farber JM; Buser KK; Darras BT; Kang PB; Riley SO; Shriber E; Parad R; Bushby K; Eagle M;
    Neuromuscul Disord; 2013 Jul; 23(7):529-39. PubMed ID: 23726376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Commonly available outcome measures for use in Indian boys with Duchenne muscular dystrophy.
    Arora H
    Neurol India; 2018; 66(5):1279-1285. PubMed ID: 30232985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study.
    Mazzone E; Vasco G; Sormani MP; Torrente Y; Berardinelli A; Messina S; D'Amico A; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Bonfiglio S; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Gasperini S; Previtali S; Napolitano S; Martinelli D; Bruno C; Vita G; Comi G; Bertini E; Mercuri E
    Neurology; 2011 Jul; 77(3):250-6. PubMed ID: 21734183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Utilization of T1-Mapping for the pelvic and thigh muscles in Duchenne Muscular Dystrophy: a quantitative biomarker for disease involvement and correlation with clinical assessments.
    Peng F; Xu H; Song Y; Xu K; Li S; Cai X; Guo Y; Gong L
    BMC Musculoskelet Disord; 2022 Jul; 23(1):681. PubMed ID: 35842609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy.
    Tsabari R; Simchovitz E; Lavi E; Eliav O; Avrahami R; Ben-Sasson S; Dor T
    Neuromuscul Disord; 2021 Sep; 31(9):803-813. PubMed ID: 34304968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longitudinal community walking activity in Duchenne muscular dystrophy.
    Fowler EG; Staudt LA; Heberer KR; Sienko SE; Buckon CE; Bagley AM; Sussman MD; McDonald CM
    Muscle Nerve; 2018 Mar; 57(3):401-406. PubMed ID: 28692198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy.
    Barnard AM; Willcocks RJ; Finanger EL; Daniels MJ; Triplett WT; Rooney WD; Lott DJ; Forbes SC; Wang DJ; Senesac CR; Harrington AT; Finkel RS; Russman BS; Byrne BJ; Tennekoon GI; Walter GA; Sweeney HL; Vandenborne K
    PLoS One; 2018; 13(3):e0194283. PubMed ID: 29554116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment.
    Romano A; Favetta M; Schirinzi T; Summa S; Minosse S; D'Amico A; Catteruccia M; Petrarca M; Castelli E; Bertini E; Vasco G
    Neuromuscul Disord; 2019 Dec; 29(12):920-929. PubMed ID: 31791868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy.
    Mayhew AG; Moat D; McDermott MP; Eagle M; Griggs RC; King WM; James MK; Muni-Lofra R; Shillington A; Gregson S; Pallant L; Skura C; Staudt LA; Eichinger K; McMurchie H; Rabb R; Di Marco M; Brown S; Zanin R; Arnoldi MT; McIntyre M; Wilson A; Alfano LN; Lowes LP; Blomgren C; Milev E; Iodice M; Pasternak A; Chiu A; Lehnert I; Claus N; Dieruf KA; Rolle E; Nicorici A; Andres B; Hobbiebrunken E; Roetmann G; Kern V; Civitello M; Vogt S; Hayes MJ; Scholtes C; Lacroix C; Gunn T; Warner S; Newman J; Barp A; Kundrat K; Kovelman S; Powers PJ; Guglieri M;
    Neuromuscul Disord; 2022 Jun; 32(6):460-467. PubMed ID: 35618576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients.
    Beenakker EA; Maurits NM; Fock JM; Brouwer OF; van der Hoeven JH
    Eur J Paediatr Neurol; 2005; 9(6):387-93. PubMed ID: 16102988
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Muscle MRI: A biomarker of disease severity in Duchenne muscular dystrophy? A systematic review.
    Ropars J; Gravot F; Ben Salem D; Rousseau F; Brochard S; Pons C
    Neurology; 2020 Jan; 94(3):117-133. PubMed ID: 31892637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Motor assessment in patients with Duchenne muscular dystrophy.
    Diniz GP; Lasmar LM; Giannetti JG
    Arq Neuropsiquiatr; 2012 Jun; 70(6):416-21. PubMed ID: 22699538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progression of muscular co-activation and gait variability in children with Duchenne muscular dystrophy: A 2-year follow-up study.
    Rinaldi M; Petrarca M; Romano A; Vasco G; D'Anna C; Bibbo D; Schmid M; Castelli E; Conforto S
    Clin Biomech (Bristol, Avon); 2020 Aug; 78():105101. PubMed ID: 32652381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reliability and validity of the Thai version of the Pediatric Quality of Life inventory™ 3.0 Duchenne Muscular Dystrophy module in Thai children with Duchenne Muscular Dystrophy.
    Thongsing A; Likasitwattanakul S; Sanmaneechai O
    Health Qual Life Outcomes; 2019 May; 17(1):76. PubMed ID: 31046775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment.
    Le Moing AG; Seferian AM; Moraux A; Annoussamy M; Dorveaux E; Gasnier E; Hogrel JY; Voit T; Vissière D; Servais L
    PLoS One; 2016; 11(6):e0156696. PubMed ID: 27271157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.